Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495802 | 0.90 | ALDH1A1 (0.58) | NPC1RAB9AGABRA5ALDH1A1ALDH1A3 | |
| SCHEMBL4509398 | 0.88 | ALDH1A1 (0.50) | NPC1RAB9AL3MBTL1ALDH1A1ALDH1A3 | |
| SCHEMBL4488743 | 0.81 | HPGDS (0.43) | NPC1RAB9AGABRA5ALDH1A1ALDH1A3 | |
| SCHEMBL4501838 | 0.80 | NPC1 (0.61) | NPC1RAB9AL3MBTL1ALDH1A1ALDH1A3 | |
| SCHEMBL4507738 | 0.80 | GABRA5 (0.54) | GABRA5AKT1AKT2 | |
| SCHEMBL14562176 | 0.80 | GABRA5 (0.53) | NPC1RAB9AL3MBTL1GABRA5ALDH1A1 | |
| SCHEMBL4493863 | 0.80 | HPGDS (0.62) | GABRA5MAPK14 | |
| SCHEMBL4500011 | 0.80 | SMN1; SMN2 (0.54) | NPC1RAB9AL3MBTL1GABRA5CYP2C19 | |
| SCHEMBL4490907 | 0.79 | MAPK14 (0.45) | NPC1RAB9AGABRA5ALDH1A1ALDH1A3 | |
| SCHEMBL4492709 | 0.78 | HPGDS (0.58) | GABRA5MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | claimed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | claimed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | claimed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | GABRA5, GABRA4, GABRA1 | NPC1 1614/4885RAB9A 1607/4885L3MBTL1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.